open access

Vol 17, No 1 (2012)
Published online: 2012-01-01
Submitted: 2010-06-22
Get Citation

Comparison of hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray

Anna Malicka-Durczak, Konstanty Korski, Matthew Ibbs
DOI: 10.1016/j.rpor.2011.10.005
·
Rep Pract Oncol Radiother 2012;17(1):44-49.

open access

Vol 17, No 1 (2012)
Published online: 2012-01-01
Submitted: 2010-06-22

Abstract

Background

This project compared HER-2/neu gene status in breast cancers, as demonstrated by FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization) and using a tissue microarray (TMA). The study also aimed to show whether the TMA technique could be used in clinical diagnostics, rather than remain a scientific tool.

Materials and methods

A TMA was constructed using 121 breast cancer specimens, 6 cores from each specimen. Demonstration and assessment of HER-2/neu gene status was by FISH (Vysis Path) and CISH (DAKO Duo CISH).

Results

The 121 breast cancer specimens were divided into 3 groups by HER-2 status, as determined by immunohistochemistry. In the HER-2 negative group no amplification was observed in 36 out of 40 cases. 3 cases showed amplification by both methods and one by CISH alone. The equivocal HER-2 group showed no amplification in 30 out of 41 cases and amplification in 9 cases. One case was FISH negative CISH positive and one was discarded. In the HER-2 positive group, amplification was confirmed in 37 of the 40 cases by both methods. 3 cases were unsuitable for assessment.

Conclusions

This study indicated that CISH is a sensitive alternative to FISH in detecting HER2 gene amplification and may replace FISH in HER2 testing. Good agreement was observed between methods (98.5% – 119 out of 121 cases).

Furthermore, as only 4 out of 121 cases were unsuitable for assessment (no signal or missing TMA cores) – it may be feasible to use TMA in diagnostics.

Abstract

Background

This project compared HER-2/neu gene status in breast cancers, as demonstrated by FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization) and using a tissue microarray (TMA). The study also aimed to show whether the TMA technique could be used in clinical diagnostics, rather than remain a scientific tool.

Materials and methods

A TMA was constructed using 121 breast cancer specimens, 6 cores from each specimen. Demonstration and assessment of HER-2/neu gene status was by FISH (Vysis Path) and CISH (DAKO Duo CISH).

Results

The 121 breast cancer specimens were divided into 3 groups by HER-2 status, as determined by immunohistochemistry. In the HER-2 negative group no amplification was observed in 36 out of 40 cases. 3 cases showed amplification by both methods and one by CISH alone. The equivocal HER-2 group showed no amplification in 30 out of 41 cases and amplification in 9 cases. One case was FISH negative CISH positive and one was discarded. In the HER-2 positive group, amplification was confirmed in 37 of the 40 cases by both methods. 3 cases were unsuitable for assessment.

Conclusions

This study indicated that CISH is a sensitive alternative to FISH in detecting HER2 gene amplification and may replace FISH in HER2 testing. Good agreement was observed between methods (98.5% – 119 out of 121 cases).

Furthermore, as only 4 out of 121 cases were unsuitable for assessment (no signal or missing TMA cores) – it may be feasible to use TMA in diagnostics.

Get Citation

Keywords

Breast cancer; CISH (duo-CISH); FISH; HER-2; Tissue microarray

About this article
Title

Comparison of hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 17, No 1 (2012)

Pages

44-49

Published online

2012-01-01

DOI

10.1016/j.rpor.2011.10.005

Bibliographic record

Rep Pract Oncol Radiother 2012;17(1):44-49.

Keywords

Breast cancer
CISH (duo-CISH)
FISH
HER-2
Tissue microarray

Authors

Anna Malicka-Durczak
Konstanty Korski
Matthew Ibbs

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl